We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
2,800,000 packets of paracetamol will be distributed to leading UK supermarkets and retailers.
First published during the 2019 to 2022 Johnson Conservative government
Ketamine should be upgraded to a Class B drug following increased evidence of bladder damage from frequent misuse, experts have recommended.
Letters were sent about tofacitinib (Xeljanz▼), Trisenox (arsenic trioxide), lapatinib (Tyverb), direct-acting oral anticoagulants, and Lartruvo▼ (olaratumab). Alerts were issued about Epanutin (phenytoin) oral solution, Macopharma intravenous infusion bags, and Co-amoxiclav (amoxicillin/clavulanic acid).
Healthcare professionals should advise patients and/or carers of the changes in the dose, packaging, dose dispenser and leaflet.
Government response to the ACMD's advice on the synthetic opioid AH-7921, a number of LSD related compounds and tryptamine.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
Monitor patients for signs and symptoms of hypercalcaemia after discontinuation of denosumab treatment for giant cell tumour of bone. Cases of rebound hypercalcemia have been reported up to 9 months after cessation of treatment.
People now need to have a medical assessment before taking domperidone to determine if it is suitable for them due to the risk of cardiac side effects.
Proton pump inhibitors (PPIs) are associated with very infrequent cases of subacute cutaneous lupus erythematosus (SCLE), a non-scarring dermatosis that can develop in sun-exposed areas.
Last month, letters were sent regarding SGLT2 inhibitors and Xgeva▼ (denosumab).
Severe infusion-related hypersensitivity reactions have occurred in patients receiving temsirolimus.
There have been reports of acute pancreatitis associated with drugs in the dipeptidylpeptidase-4 (DPP-4) inhibitor class of antidiabetic agents (‘gliptins’).
Further evidence that the cardiovascular risk with diclofenac is higher than other non-selective NSAIDs and similar to the selective COX-2 inhibitors.
Hospira UK Limited (Pfizer) is recalling specific batches as a precautionary measure.
In November, letters were sent regarding thalidomide, mycophenolate mofetil, nicorandil, InductOs, and dimethyl fumarate
In March 2016, letters were sent regarding SGLT2 inhibitors, insulin lispro, natalizumab, noradrenaline, radium-223 dichloride, aflibercept and idelalisib.
Indication restricted to nausea and vomiting, new contraindications, and reduced dose and duration of use.
Letters were sent about methotrexate, modafinil, Ecalta, Picato, Nexplanon, valproate medicines, e-cigarettes, and Lemtrada. Alerts were issued about finasteride, codeine/paracetamol, and Picato.
If new movement disorders occur during treatment consider dose reduction or a gradual discontinuation of treatment in consultation with specialist advice.
Letters were sent about INOmax (nitric oxide) cylinders and triptorelin (Decapeptyl).
Oral diclofenac is associated with a small increased risk of cardiovascular side effects and is therefore no longer available over the counter.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).